Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:683-684 (6 October), doi:10.1136/bmj.39346.496690.3A
| The first 150 words of the full text of this article appear below. |
Magrini and Font discuss direct to consumer advertising,1 but drug promotion at an earlier stage may have already influenced the views of the public and patients.
Current European legislation on drug promotion makes it difficult to define what promotion by a pharmaceutical company before market authorisation entails. Many drug companies employ marketing companies to promote new drugs. The recent premature promotion of Herceptin for early breast cancer is viewed as exemplary by the industry and to be copied.
Releasing early results from high profile trials at major cancer conferences can gain worldwide publicity. When supported by website press releases to inform the stock market, one sided information is freely available in the market place.
The small patient group "Women Fighting for Herceptin" was supported by a leading marketing company.2 The ensuing national media campaign pushed politicians into supporting the unlicensed use of Herceptin and hence undermined the UK Medicines Act
Jonathan V Howell, consultant in public health
West Midlands Specialised Commissioning Team, Edwin House, Burton on Trent DE14 2WF
jonathan.howell@lycos.com